Magnitude and associated factors of poor medication adherence among diabetic and hypertensive patients visiting public health facilities in Ethiopia during the COVID-19 pandemic.
Adult
Antihypertensive Agents
/ administration & dosage
COVID-19
/ epidemiology
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ drug therapy
Ethiopia
/ epidemiology
Female
Follow-Up Studies
Humans
Hypertension
/ drug therapy
Hypoglycemic Agents
/ administration & dosage
Male
Medication Adherence
Middle Aged
Pandemics
COVID-19 Drug Treatment
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
10
2020
accepted:
12
03
2021
entrez:
6
4
2021
pubmed:
7
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
This study aims to assess the magnitude and associated factors of poor medication adherence among diabetic and hypertensive patients visiting public health facilities in Addis Ababa, Ethiopia during the COVID-19 pandemic. A multi-site cross-sectional design was conducted from 1st through 30th of August 2020 at public health facilities of the study area. Adult outpatients with T2DM and hypertension visiting hospitals and health centers were included in the study. A proportion to size allocation method was used to determine the required sample size per facility. Data was collected using the 8-item Morisky medication adherence scale. Descriptive statistics and binary logistic regression were used to analyze data. A 95% confidence interval and p≤0.05 statistical significance was considered to determine factors associated with poor medication adherence. A total of 409 patients were included in the present study. About 57% of the patients reported that the COVID-19 pandemic has posed negative impacts on either of their follow-up visits, availability of medications, or affordability of prices. And, 21% have reported that they have been affected in all aspects. The overall magnitude of poor medication adherence was 72%. Patients with extreme poverty were more likely to have good medication adherence (AOR: 0.59; 95%C.I: 0.36-0.97), whereas attendance to a health center (AOR: 1.71; 95%C.I: 1.02-2.85), presence of comorbidity (AOR: 2.05; 95%C.I: 1.13-3.71), and current substance use history (AOR: 11.57; 95%C.I: 1.52-88.05) predicted high odds of poor adherence. Over a three-fourth of the patients, in the study setting, have poor adherence to their anti-diabetic and antihypertensive medications. Health facility type, income level, comorbidity, and current substance use history showed a statistically significant association with poor adherence to medication. Stakeholders should set alternative strategies as perceived impacts of the COVID-19 pandemic on medication adherence are high in the study area.
Identifiants
pubmed: 33822807
doi: 10.1371/journal.pone.0249222
pii: PONE-D-20-34174
pmc: PMC8023457
doi:
Substances chimiques
Antihypertensive Agents
0
Hypoglycemic Agents
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249222Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Hum Hypertens. 2000 Aug;14(8):489-96
pubmed: 10962516
BMJ. 2008 May 17;336(7653):1114-7
pubmed: 18480115
PLoS One. 2018 Mar 28;13(3):e0193995
pubmed: 29590156
Int J Health Sci (Qassim). 2017 Sep-Oct;11(4):47-52
pubmed: 29085268
BMC Res Notes. 2017 Dec 4;10(1):676
pubmed: 29202857
BMC Health Serv Res. 2014 Sep 24;14:431
pubmed: 25253270
Res Social Adm Pharm. 2021 Jan;17(1):2023-2026
pubmed: 32307319
J Health Popul Nutr. 2019 Jan 24;38(1):4
pubmed: 30678724
Ther Clin Risk Manag. 2005 Sep;1(3):189-99
pubmed: 18360559
PLoS One. 2019 Oct 1;14(10):e0222985
pubmed: 31574113
BMC Res Notes. 2018 Jan 15;11(1):27
pubmed: 29335003
Health Aff (Millwood). 2002 Mar-Apr;21(2):31-46
pubmed: 11900185
PLoS One. 2015 Mar 27;10(3):e0120560
pubmed: 25816353
Pan Afr Med J. 2020 Jun 08;35(Suppl 2):66
pubmed: 33623590
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):965-967
pubmed: 32604016
Pan Afr Med J. 2020 Jun 29;35(Suppl 2):94
pubmed: 33623618
Diabetes Metab Syndr Obes. 2013 Nov 06;6:421-6
pubmed: 24232691
J Psychosoc Rehabil Ment Health. 2020 Aug 25;:1-5
pubmed: 32864302
J Behav Med. 1987 Aug;10(4):377-94
pubmed: 3669072
Med Clin North Am. 2017 Jan;101(1):229-245
pubmed: 27884232
BMC Fam Pract. 2020 Dec 5;21(1):255
pubmed: 33278877
PLoS One. 2018 Jun 1;13(6):e0197482
pubmed: 29856753
PLoS One. 2013 Apr 25;8(4):e62775
pubmed: 23638143
JRSM Cardiovasc Dis. 2019 Dec 13;8:2048004019892758
pubmed: 32010442
Diabetol Metab Syndr. 2020 Jul 16;12:62
pubmed: 32695232
Expert Opin Drug Saf. 2017 Feb;16(2):203-213
pubmed: 27885844
Diabetes Metab Syndr Obes. 2020 Feb 25;13:501-508
pubmed: 32158245
JAMA. 2002 Dec 11;288(22):2880-3
pubmed: 12472330
Integr Blood Press Control. 2017 Jun 16;10:1-7
pubmed: 28670137
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
BMC Public Health. 2012 Nov 20;12:1007
pubmed: 23167315
J Nurs Scholarsh. 2003;35(3):207
pubmed: 14562485
Bull World Health Organ. 2002;80(1):33-9
pubmed: 11884971
BMC Res Notes. 2019 Feb 14;12(1):87
pubmed: 30764864
Ann Intern Med. 2012 Dec 4;157(11):785-95
pubmed: 22964778
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
Mayo Clin Proc. 2011 Apr;86(4):304-14
pubmed: 21389250
Am J Cardiol. 1993 Sep 30;72(10):68D-74D
pubmed: 8213501